TherapeuticsMD (NASDAQ:TXMD) Research Coverage Started at assumed coverage on shares of TherapeuticsMD (NASDAQ:TXMDFree Report) in a research report released on Thursday morning. The brokerage issued a hold rating on the stock.

TherapeuticsMD Stock Performance

Shares of TherapeuticsMD stock opened at $2.10 on Thursday. The stock’s 50-day moving average is $2.06 and its 200 day moving average is $2.26. TherapeuticsMD has a one year low of $1.84 and a one year high of $4.43.

TherapeuticsMD (NASDAQ:TXMDGet Free Report) last issued its quarterly earnings results on Friday, May 10th. The company reported ($0.07) earnings per share (EPS) for the quarter. The business had revenue of $0.31 million during the quarter.

Institutional Investors Weigh In On TherapeuticsMD

A hedge fund recently bought a new stake in TherapeuticsMD stock. Prosperity Consulting Group LLC bought a new stake in TherapeuticsMD, Inc. (NASDAQ:TXMDFree Report) in the 1st quarter, according to its most recent 13F filing with the SEC. The firm bought 24,500 shares of the company’s stock, valued at approximately $56,000. Prosperity Consulting Group LLC owned 0.21% of TherapeuticsMD at the end of the most recent reporting period. Institutional investors own 30.74% of the company’s stock.

About TherapeuticsMD

(Get Free Report)

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.

Featured Stories

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with's FREE daily email newsletter.